Overestimated treatment effects in randomised phase II trials: What's up doctor?
European Journal of Cancer
MetadataПоказать полную информацию
Michiels, S., & Wason, J. (2019). Overestimated treatment effects in randomised phase II trials: What's up doctor?. European Journal of Cancer, 123 116-117. https://doi.org/10.1016/j.ejca.2019.09.023
Phase II clinical trials of experimental treatments play an essential role in drug development. Historically, trials were conducted sequentially, starting from a phase I trial in which dose and safety are evaluated advancing to phase II, looking for some sign of efficacy on a short-term end-point such as tumour shrinkage to screen out inefficacious experimental agents, and to large-scale randomised phase III trials evaluating properly the efficacy of a new treatment on objective clinical end-points. To expedite this process, phase II trials historically used single-arm designs to treat patients with experimental therapies only . However, the overall success rate of drug development programs in oncology from the start of phase I to registration has been estimated recently to be only 3.4%, much lower compared with that of other diseases . Part of this low success rate has been argued to be due to suboptimal use of randomised trial designs in the phase II space.
Cancer Research UK (18113)
External DOI: https://doi.org/10.1016/j.ejca.2019.09.023
This record's URL: https://www.repository.cam.ac.uk/handle/1810/298852
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/